-
IMPORTANT: SATURDAY EVENING, JUNE 1 we will be upgrading the message board software. We expect minimal downtime during the upgrade, and we will attempt to complete this during low-traffic hours.Dismiss Notice
In preparation for the upgrade, we will be performing board maintenance, such as moving boards to Lost Civilizations where appropriate. Lost Civilizations is a category for companies that have either been dissolved or acquired. The boards serve as both an archive of the old company posts, as well as a place for former employees to reminisce or reconnect, as they will remain open for posting. We may also remove some board threads that have been inactive for several years.
Recent Posts
-
Davide Piras
It’s the only thing that makes sense but then I’ve learned the hard way that “sense” and “BMS” have a tenuous relationship at best.
-
Novartis study points to larger role for targeted leukemia drug
via People with chronic myeloid leukemia, a simmering cancer of the bone marrow, are often treated with one of several targeted drugs that, over the past two decades, have helped to substantially prolong survival from the disease. Study results...
-
Dupixent nears EU approval for COPD, as FDA delays
via Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive pulmonary disease (COPD). article source
-
Novartis cues up filings for remibrutinib in chronic hives
via Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long-term data from two phase 3 trials. article source
-
Ultragenyx Pharmaceutical Says Glycogen Storage Disease Treatment Met Endpoints
via Ultragenyx Pharmaceutical on Thursday said its potential treatment for glycogen storage disease type 1a met multiple endpoints in a clinical study. The Novato, Calif.-based biopharmaceutical company said its gene therapy DTX401 had resulted...
-
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
via Pfizer (PFE.N) said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the strength of data presented on Friday showing most patients treated for a rare form of advanced lung cancer in a clinical trial were alive...
-
Phathom
Put in for it ASAP as senior management has said they will not approve vacations during summer launch timeframe.
- + Show More
-
General Discussion
Discussion boards of general interest for those in the pharma, biotech, medical device, and related industries
-
Pharma/Biotech Companies
Anonymous discussion boards for pharmaceutical and biotech companies
-
Regional Discussion and Job Opportunities
Discussion and job opportunities by region
-
Lost Civilizations
Anonymous discussion boards for pharma/medical companies that no longer exist due to acquisition or other factors
-
Laboratory/Diagnostic Sales
Anonymous discussion boards for lab sales/diagnostics companies
-
Animal Health Sales
Anonymous discussion boards for animal health companies
-
Medical Equipment/Device Sales
Anonymous discussion boards for medical equipment/device companies
-
Pharmacies
Anonymous boards for pharmacy employees
-
PBMs
Anonymous discussion boards for PBMs
-
Pharma/Healthcare Marketing Agencies
Anonymous discussion boards for pharma/healthcare marketing agencies
-
Dental Reps
Anonymous discussion boards for dental health companies
-
Managed Care Specialists
Anonymous discussion boards for managed care specialists
-
Pharma IT
Anonymous discussion boards for pharma IT employees